CT结肠成像用于结直肠癌筛查与预防:美国一家学术医学中心20年项目经验
该回顾性研究报告单中心2004年4月至2024年3月共11830例患者15431次CT结肠成像检查,其中9168次为无症状初次筛查;无结肠穿孔或重大并发症,≥6 mm息肉阳性率15.9%,光学结肠镜转诊率10.5%,≥6 mm息肉阳性预测值91.6%,结论支持CTC作为安全的无创筛查手段但利用率下降。
要点
- 无症状筛查中≥6 mm息肉CTC阳性率15.9%,≥10 mm为5.7%,≥3 cm肿块为0.6%。
- ≥6 mm息肉光学结肠镜阳性预测值为91.6%(1541/1683)。
- 无症状筛查中偶然发现的结肠外恶性肿瘤和腹主动脉瘤分别占0.4%和0.3%。
核心结论
- 研究结果支持CTC作为一种安全的无创检查用于结直肠癌预防和检出,并附带结肠外评估,但同时也凸显该检查利用率下降。
研究设计与样本
- 单中心回顾性研究,纳入2004年4月至2024年3月全部CTC检查,共11830例患者15431次检查,数据来自同期维护的CTC数据库,并汇总与后续光学结肠镜结果的相关性。
关键影像表现/征象
- 无症状筛查组CTC检出≥6 mm息肉2192枚中,61.5%为无蒂、18.3%为平坦、16.9%为有蒂,45.1%位于右侧。
- 无症状筛查组中≥6 mm息肉经光学结肠镜证实一致病变1541枚,阳性预测值91.6%。
- 无症状筛查组每次检查光学结肠镜检出最具侵袭性组织学为腺癌0.2%(21/9168)、进展期腺瘤4.0%(367/9168)、非进展期管状腺瘤3.4%(310/9168)、无蒂锯齿状病变0.5%(44/9168)、增生性息肉1.2%(112/9168)、其他良性病理0.4%(33/9168)。
- 无症状筛查组中0.4%的检查发现后续证实的偶然结肠外恶性肿瘤,0.3%发现偶然腹主动脉瘤。
- 2005年和2023年(分别为完整数据可获取的首年和最后一年)初次无症状筛查分别为1589次和72次检查,常规筛查和息肉监测的随访CTC分别为2886次和616次检查。
诊断标准与关键数值
- 无症状初次筛查组CTC阳性定义:≥6 mm息肉阳性率15.9%(1459/9168),10-29 mm息肉阳性率5.7%(526/9168),≥3 cm肿块阳性率0.6%(56/9168)。
- 无症状筛查组光学结肠镜转诊率10.5%(969/9169)。
- ≥6 mm息肉光学结肠镜阳性预测值91.6%(1541/1683)。
临床应用与阅片要点
- 20年项目经验可作为计划开展CTC筛查项目的机构基准。
- CTC筛查可同时评估结肠外偶然发现,包括结肠外恶性肿瘤和腹主动脉瘤。
- 研究期间未发生结肠穿孔或其他重大并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Utilization of CT colonography (CTC) as a screening test for colorectal cancer (CRC) may increase after the start of CMS coverage in January 2025. OBJECTIVE. The purpose of this study was to report 20-year programmatic results of a large institutional screening-focused CTC program. METHODS. This retrospective study included all CTC examinations performed from April 2004 through March 2024 at a single institution that has adopted CTC standardization and quality assurance measures. Data were extracted from a contemporaneously maintained CTC database. Programmatic experience was summarized, including correlation with subsequent optical colonoscopy (OC) findings. RESULTS. A total of 11,830 patients (6528 women and 5302 men; mean age, 56.0 years) underwent 15,431 CTC examinations; 99.3% were covered by commercial insurance or third-party payers. No colonic perforations or other major complications occurred. A total of 9168 examinations in 9168 patients were performed for primary asymptomatic screening. These examinations were positive for a polyp 6 mm or larger in 15.9% (1459/9168), a polyp 10-29 mm in 5.7% (526/9168), and a mass 3 cm or larger in 0.6% (56/9168). Of 2192 CTC-detected polyps that were at least 6 mm in this group, 61.5% were sessile, 18.3% were flat, and 16.9% were pedunculated; 45.1% were right-sided. The OC referral rate in this group was 10.5% (969/9169). Of 1683 polyps 6 mm or greater that underwent OC, concordant lesions were found in 1541 (PPV = 91.6%). Per examination, the most aggressive histology detected on OC included adenocarcinoma (0.2%; 21/9168), advanced adenoma (4.0%; 367/9168), nonadvanced tubular adenoma (3.4%; 310/9168), sessile serrated lesion (0.5%; 44/9168), hyperplastic polyp (1.2%; 112/9168), and other benign pathology (0.4%; 33/9168). In the asymptomatic screening group, 0.4% and 0.3% of examinations detected a subsequently confirmed incidental extracolonic malignancy and an incidental abdominal aortic aneurysm, respectively. A total of 1589 and 72 examinations were performed for primary asymptomatic screening in 2005 and 2023 (the first and last years of complete data availability, respectively). A total of 2886 and 616 follow-up CTC examinations were performed for routine screening and polyp surveillance, respectively. CONCLUSION. The findings support CTC screening as a safe noninvasive test for CRC prevention and detection with additional extracolonic assessment, although they also highlight the examination's decreasing utilization. CLINICAL IMPACT. These 20-year programmatic results can provide benchmarks for practices seeking to start CTC screening programs.
引用
- Pickhardt PJ, Golden MV, Kim DH, et al. CT Colonography for Colorectal Cancer Screening and Prevention: 20-Year Programmatic Experience at a U.S. Academic Medical Center. AJR Am J Roentgenol. 2025. PMID: 40699017. doi:10.2214/AJR.25.33288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。